Hester Biosciences Ltd (HESTERBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Hester Biosciences Ltd on NSE and BSE, with an AI summary of each filing.
This is to inform you that, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has scheduled investor ....
Intimation · 05 Nov 2026, 2:00 pm
Hester Biosciences Schedules Q2 & H1 FY27 Earnings Conference Call Hester Biosciences Limited will host an earnings conference call on 5th Nov'26 at 2:00 PM IST to discuss its financial performance for the quarter and half-year ended 30th Sep'26 (Q2 & H1 FY27). The call is organized by ICICI Securities and will feature senior management, including CEO & Managing Director Rajiv Gandhi, Executive Director Priya Gandhi, and CFO Ashish Desai.
HESTER BIOSCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
HESTER BIOSCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Hester Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited standalone and ....
Intimation · 05 Nov 2026, 5:30 am
Hester Biosciences Schedules Board Meeting to Consider Q2 Results Hester Biosciences Limited has scheduled a meeting of its Board of Directors on 5th Nov'26. The board will meet, inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and six-month period ended 30th Sep'26, in compliance with Regulation 29 of SEBI LODR Regulations.
Disclosure under Regulation 30 of the SEBI Listing Regulations - Completion of tenure of Independent Director Mr. Ameetkumar Desai with effect from closure of business hours on 27 October ....
Others (Uncategorized) · 27 Oct 2026, 4:16 pm
Hester Biosciences: Independent Director Ameetkumar Desai Completes Board Tenure Hester Biosciences Limited announced that Independent Director Mr. Ameetkumar Desai (DIN: 00007116) has decided not to seek reappointment for a second consecutive term. Consequently, Mr. Desai ceased to be an Independent Director of the company effective from the close of business hours on 27th Oct'26 upon the completion of his first term, in compliance with Regulation 30 of the SEBI Listing Regulations.
Disclosure under Regulation 30 of the SEBI Listing Regulation for Investment in Limited Liability Partnership for Group Captive Power Generation
Others (Uncategorized) · 06 Oct 2026, 4:59 pm
Hester Biosciences Approves INR 10.50 Million Investment for 26% Stake in Slyce Agri World Hester Biosciences' board approved a capital contribution of up to INR 10.50 mn in Slyce Agri World LLP for a 26% stake to secure group captive solar power under a Power Purchase Agreement. The cash transaction satisfies regulatory norms to make Hester the sole captive power consumer and is slated for completion within six months. Slyce Agri World, an Ahmedabad-based renewable energy generator, posted revenues of INR 22.40 mn in FY25, INR 40.86 mn in FY24, and INR 1.30 mn in FY23.
Outcome of Board Meeting and Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Investment in Limited Liability Partnership ....
Others (Uncategorized) · 06 Oct 2026, 4:55 pm
Hester Biosciences Approves 26% Stake Acquisition in Slyce Agri World LLP Hester Biosciences approved a capital contribution of up to INR 10.50 million in one or more tranches to acquire a 26% stake in Slyce Agri World LLP, a renewable energy SPV. The cash transaction enables Hester to source group captive solar power and fulfill statutory captive power compliance under GERC/CERC norms via a Power Purchase Agreement. The acquisition is not a related-party transaction and is slated for completion within six months. Slyce Agri World reported FY24-25 turnover of INR 22.40 million.
Shareholders'' approval for Reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter and Promoter Group category to Public Category shareholders of the Company.
Others (Uncategorized) · 04 Sept 2026, 7:00 pm
Hester Biosciences Approves Promoter Reclassification of Ravin and Bela Gandhi to Public Category Hester Biosciences' shareholders approved the reclassification of promoters Mr. Ravin Gandhi (403,320 shares; 4.74% stake) and Ms. Bela Gandhi (400,635 shares; 4.71% stake) to the "Public" category via postal ballot on 3rd Sep'26. The ordinary resolution passed with 99.99% majority support across 39,81,536 valid votes polled (46.81% turnout), following prior no-objection clearances from BSE and NSE on 24th Jul'26. Both individuals will now be excluded from promoter group reporting, with the company confirming continued compliance with minimum public shareholding norms under SEBI regulations.
Intimation of Upgrade in Credit Ratings by Care Ratings Limited
Others (Uncategorized) · 28 Aug 2026, 12:57 am
Hester Biosciences Credit Ratings Upgraded by CARE Ratings CARE Ratings upgraded Hester Biosciences' credit ratings on 27 Aug'26, reflecting improved operational and financial performance. Long-term bank facilities (₹48.45 crore) were raised to 'CARE BBB+; Stable' from 'CARE BBB; Stable'. Short-term facilities (₹0.22 crore) were upgraded to 'CARE A2' from 'A3+'. Similarly, Long/Short-term facilities (₹65.00 crore) were revised to 'CARE BBB+; Stable / CARE A2'. The upgrade signals enhanced creditworthiness, potentially lowering borrowing costs and improving financial flexibility for the company's total rated facilities of ₹113.67 crore.
Transcript of Earnings Conference Call held on 30 July 2026
Transcript · 01 Aug 2026, 7:45 pm
Hester Biosciences Q1FY27: Strong Standalone Growth, Consolidated Operations Drag Hester Biosciences reported strong Q1FY27 standalone results with revenue up 14% YoY and PAT increasing 88% YoY. Gross margins improved from 69% to 78%, driven by a favorable product mix. The Poultry Healthcare division grew 48% YoY, offsetting weakness in the Animal Healthcare division caused by delayed government tenders. Consolidated revenue declined 8% YoY due to lower revenues from Nepal and Africa. Hester Africa's loan was restructured by the Gates Foundation, reducing the principal from USD 12M to USD 5M, resulting in an exceptional gain. Consolidated debt was Rs. 103 crores.
Launch of Interactive Microsite of 39th Annual Report FY 2025-26
Annual Report · 31 Jul 2026, 9:10 pm
Audio recording of the Earnings Conference Call held on 30 July 2026
Audio / Video · 30 Jul 2026, 10:16 pm
Hester Biosciences Makes Q1FY27 Earnings Call Recording Available Hester Biosciences has released the audio recording of its earnings conference call held on 30 Jul'26. The call discussed the company's financial results for the quarter ended 30 Jun'26. In compliance with SEBI regulations, the recording is now accessible on the company's official website for investor reference.
20260730 Q1 FY27 Press Release
Press Release · 30 Jul 2026, 5:05 pm
Hester Biosciences: Exceptional Gain Drives 459% YoY Consolidated Q1 PAT Growth Hester Biosciences reported mixed Q1 FY27 results for the quarter ended 30 Jun'26. Consolidated PAT surged 459% YoY to INR 967.3M, driven by an INR 853.5M exceptional gain from a loan amendment at Hester Africa. Consolidated revenue declined 8% YoY to INR 772.4M due to lower Nepal and Africa sales. Standalone revenue grew 14% YoY to INR 726.6M, led by a 48% rise in Poultry Healthcare. However, Animal Healthcare sales fell 50% YoY, impacted by delays in government tender execution.
Financial Results and Press Release for the Quarter ended 30 June 2026
Financial Result · 30 Jul 2026, 4:54 pm
Hester Biosciences Q1FY27 Consolidated PAT Surges on Exceptional Gain Hester Biosciences reported Q1FY27 consolidated PAT at INR 967.3M, up 459% YoY, driven by an INR 853.5M exceptional gain from a subsidiary's loan amendment. Revenue from operations declined 8% YoY to INR 772.4M, impacted by lower sales in Nepal and Africa. The standalone business saw revenue grow 14% to INR 726.6M, with PAT up 88% to INR 147.1M. Strong 48% growth in the Poultry Healthcare segment offset a 50% decline in Animal Healthcare due to tender delays. Consolidated EPS stood at INR 113.71.
Outcome of Board Meeting held today
Outcome · 30 Jul 2026, 4:46 pm
Hester Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 772 (-8.2% YoY | -22.8% QoQ) ■ EBITDA: 228 (-0.2% YoY | -33.7% QoQ) ■ EBITDA Margin (%): 29.5 (+236 bps YoY | -481 bps QoQ) ■ PAT: 970 (+489.8% YoY | +506.8% QoQ) ■ EPS (INR): 113.7 (+459.3% YoY | +484.6% QoQ) Hester Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) Segmental Performance Poultry Healthcare ■ Revenue: 621 (+47.5% YoY | -4.0% QoQ) ■ EBIT: 243 (+163.4% YoY | +5.2% QoQ) ■ EBIT Margin (%): 39.1 (+1721 bps YoY | +341 bps QoQ) Animal Healthcare ■ Revenue: 151 (-64.0% YoY | -57.3% QoQ) ■ EBIT: -41.9 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -27.7 (Profit to Loss YoY | Profit to Loss QoQ)
Intimation of Earnings Conference Call schedule to be held on 30 July 2026 at 2:00 p.m. (IST) post the publication of financial results
Intimation · 30 Jul 2026, 2:00 pm
Hester Biosciences Schedules Q1FY27 Earnings Conference Call Hester Biosciences has scheduled an investor conference call on 30 Jul'26 at 2:00 p.m. IST to discuss financial results for the quarter ended 30 Jun'26. The call will be hosted by ICICI Securities and feature key management, including CEO Rajiv Gandhi, Executive Director Priya Gandhi, and CFO Ashish Desai. This event follows the public announcement of the company's Q1FY27 financial performance.
We wish to inform that NSE and BSE has issued their NOC for the re-classification application filed on 19 May 2026.The copies of NOC enclosed herewith.
Others (Uncategorized) · 25 Jul 2026, 5:47 pm
Hester Biosciences Promoters Reclassified Following Exchange Approvals Hester Biosciences announced on 25 Jul'26 that it received no-objection approvals from both the NSE and BSE for the re-classification of Mr. Ravin Gandhi and Ms. Bela Gandhi. The approvals, granted on 24 Jul'26, officially move them from the Promoter Group to the Public shareholder category. This follows the company's application originally filed on 19 May'26 under SEBI's Listing Obligations and Disclosure Requirements Regulations. The reclassification alters the company's promoter shareholding structure, a key metric for investors.
Hester Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the unaudited standalone ....
Intimation · 30 Jul 2026, 5:30 am
Hester Biosciences Board Meeting on 30 Jul'26 for Q1FY27 Results Hester Biosciences has scheduled a Board of Directors meeting on 30 Jul'26 to consider and approve its unaudited standalone and consolidated financial results for the first quarter ended 30 Jun'26. This announcement, made on 23 Jul'26, is a key event for investors tracking the company's Q1FY27 performance.
Voting Results of 39th Annual General Meeting and Scrutiniser Report
Annual General Meeting · 21 Jul 2026, 9:15 pm
Outcome of 39th Annual General Meeting, Voting Results and Scrutinizer Report of the Company
Annual General Meeting · 21 Jul 2026, 9:12 pm
Disclosure under Regulation 30 of the SEBI Listing Regulations - Sale of Equity Investment in Texas Lifesciences Private Limited
Others (Uncategorized) · 09 Jul 2026, 10:04 pm
Hester Biosciences Exits Investment in Texas Lifesciences Hester Biosciences has fully divested from Texas Lifesciences Private Limited (TLPL) by selling its remaining 11% stake on 8 Jul'26. The company transferred 543,248 equity shares to TLPL's existing shareholders for an aggregate consideration of INR 23 million. Following this transaction, Hester Biosciences' shareholding in TLPL is reduced to nil, marking a complete exit from its equity investment in the company. The sale was executed as per terms approved by the Board of Directors.
Corrigendum to the Notice convening 39th Annual General Meeting of the Company
Annual General Meeting · 08 Jul 2026, 5:54 pm
FY 2025-26 Business Responsibility and Sustainability Report
Others (Uncategorized) · 18 Jun 2026, 8:50 pm
Hester Biosciences Submits FY26 Business Responsibility and Sustainability Report Hester Biosciences filed its Business Responsibility and Sustainability Report for the year ended 31 Mar'26. Exports contributed 11% to total turnover. R&D spending on environmental/social improvements was 50.83% of total R&D, down from 64.25% YoY. Similar capex decreased to 9.19% from 23.24%. The permanent employee turnover rate increased to 39.04% from 34.05% YoY. Total Scope 1 & 2 GHG emissions fell to 8,626 metric tonnes from 9,534. Total water consumption also decreased to 36,588 KL from 47,730 KL YoY.
Record date for Dividend and AGM is Tuesday, 14 July 2026, for the purpose of determining shareholders'' entitlement for dividend, as recommended by the Board of Directors at their meeting ....
Dividend · 18 Jun 2026, 8:35 pm